CME Group Long-Term Value Investment Analysis

Hunting ten-year five-baggers among great growth stocks — pressing the upside question: "Can it get much bigger?"

• QHow high is its market ceiling? Is it expanding an existing pie, or creating an entirely new market?5/10

  A

  Conclusion: CME is mainly expanding and defending a large existing pie, rather than creating a new market. The ceiling exists and is still rising slowly, but it is not the kind of blank blue ocean Baillie Gifford prefers, where a market is created from scratch and becomes ten times larger than the current base.

  CME operates in a mature financial infrastructure industry with real long-term demand: it provides trading, clearing, settlement, and market data for risk management needs across rates, equity indexes, energy, agricultural products, metals, and foreign exchange. The pie itself is expanding. According to FIA data cited in the report, global exchange-traded derivatives volume reached 50.476 billion contracts in the first four months of 2026, up 35.6% year over year. CME's own futures and options ADV reached a record 28.129 million contracts per day in 2025, and official disclosures showed Q1 2026 ADV rising further to a quarterly record of 36.20 million contracts per day, up 22% year over year. The long-term anchor for demand is persistent real-world volatility in rates, commodities, and exchange rates, rather than investor sentiment, so the ceiling is unlikely to collapse easily.

  But the nature of that ceiling needs to be viewed honestly:

  First, this is penetration and expansion of an existing pie, not the creation of a new market. Rate futures, equity index futures, and commodity futures are mature categories that have existed for decades. CME is continuously pulling more OTC risk, more asset classes, and more regional customers into its existing clearing and liquidity network. It has edge innovations such as cryptocurrency futures and active event contracts, but these are not yet new markets large enough to change the order of magnitude.

  Second, growth is mid- to high-single-digit, not exponential. The report estimates that revenue grew from USD 4.884 billion in 2020 to USD 6.521 billion in 2025, a 5-year CAGR of about 5.9%; CME also officially confirmed that 2025 full-year revenue was about USD 6.5 billion, marking a fourth consecutive annual record. This is a high-quality but gradual growth curve. The ceiling rises naturally with global risk management demand; CME is not opening up a whole new sky by itself.

  Third, its role is closer to toll-taking infrastructure than to a disruptive new species. The pie expands mainly through growth in global notional rate and commodity exposures, the volatility environment, and the standardization of OTC risk onto exchanges. CME is the tollgate on that river, not the party digging a new channel.

  Measured by Baillie Gifford's lens of whether a company is expanding an existing pie or creating a new market, CME clearly falls into the former. It is a good business that can grow slowly with the broader market while firmly occupying a toll-taking position, but the shape of the ceiling is wide and flat, not high and steep. That is the starting point that must be recognized before judging whether it can rise fivefold over 10 years.

  Jun 11, 2026
• QCan its revenue at least double over the next five years? Will growth be driven mainly by volume, price, or new businesses?3/10

  A

  Conclusion: Almost certainly not. Doubling revenue over the next five years would require a CAGR of about 15%, while CME's history and structure both point to mid- to high-single-digit growth. Growth is driven mainly by volume, meaning trading volume and ADV, with some support from price/new business in market data, but the three together are not enough to support a five-year doubling.

  Start with what doubling requires. From a 2025 revenue base of about USD 6.5 billion, doubling in five years to about USD 13.0 billion would require roughly 14.9% annualized growth for five consecutive years. Compare that with the actual path disclosed in the report: revenue CAGR from 2020 to 2025 was only about 5.9%. Accelerating from 6% to 15% and sustaining that for five years would require a structural leap in demand or pricing. No such engine is visible today.

  Break down the sources of growth, and the ceiling is clear in each case:

  Volume, meaning trading volume/ADV, is the main engine, but elasticity is limited. About 81% of CME's revenue comes from clearing and transaction fees, essentially contract count multiplied by rate per contract. Futures and options ADV reached a record 28.129 million contracts per day in 2025, and official disclosures showed it rising to about 36.20 million contracts per day in Q1 2026, up 22% year over year. But the report makes clear that this high growth rate depends heavily on the unusually active rate, geopolitical, and commodity volatility environment at the time. It is high quality but not smooth; a single-quarter surge cannot be linearly extrapolated over five years, and volume will give back gains when volatility recedes.

  Price, meaning rate per contract, is not a tailwind and is actually a headwind. The report explicitly notes that rate per contract fell about 5% year over year in Q1 2026. Long-term pressure on fees from competition, client mix, and volume discounts means price is not only unlikely to contribute to a doubling; it is dragging growth down.

  New businesses, meaning market data/information services, are growing faster and are stickier, but the base is too small. Q1 2026 market data revenue reached a record USD 224 million. The report estimates 2025 market data revenue at about USD 803 million, only about 12% of total revenue. Even if it grows at a double-digit rate, it remains a secondary engine and cannot lift the whole company to 15% growth.

  A horizontal check points the same way: Q1 2026 total revenue was USD 1.88 billion, up 14% year over year. That 14% was achieved only in a very strong volatility quarter with ADV up 22%, while rates per contract were still falling. Once volatility normalizes, growth is likely to fall back to the mid- to high-single-digit range.

  Measured by Baillie Gifford's hard test of five-year revenue doubling, CME fails. It is a high-quality cash machine, but its growth comes from natural expansion in global risk exposures plus cyclical amplification in volume. Structurally, it is a mid- to high-single-digit compounder and cannot reach the 15% annualized growth needed for a five-year doubling. This is the key evidence that it is a good company, but not a high-growth stock.

  Jun 11, 2026
• QAfter five years, what will take over as the next growth engine? Does this second curve exist today?4/10

  A

  Conclusion: CME does not have a clear second curve capable of changing its scale. The visible candidates today, including market data/information services, crypto and new asset classes, cross-product clearing, and OTC migration, all exist and are growing, but they look more like extensions and thickening of the current main curve than independent new growth poles.

  First define the standard for a second curve: it should be an engine that is still small today but can independently carry growth in the future, even taking over when the core business slows. Against that standard, the candidates in the report and the latest data look as follows:

  Candidate 1: market data and information services. This is the closest thing to a second engine, but the scale is too small to take over. The report estimates 2025 revenue at about USD 803 million, about 12% of total revenue, with better growth and stickiness than trading and clearing. Q1 2026 set a quarterly record of USD 224 million; tools such as CME Benchmark and CME Term SOFR further strengthen pricing power. This is real and durable incremental growth, but the share is too small. Even if it continues to grow at a double-digit rate, it can only make revenue more resilient and cannot independently support overall growth if the core business slows. It thickens the curve; it does not take over.

  Candidate 2: cryptocurrency and new asset classes. The optionality exists, but the contribution is still marginal. CME has launched cryptocurrency futures and continues to expand its product set, a natural extension into new risk exposures. But the report does not list this as a quantifiable core growth pole, and new assets are precisely the most crowded and disruption-prone battleground. In early June 2026, Kalshi won approval for bitcoin perpetual contracts, and TD Cowen warned that such products could pressure valuation multiples for CME, ICE, and CBOE, showing that new assets are not only an opportunity for CME but also a risk.

  Candidate 3: cross-product clearing efficiency and OTC migration. This reinforces the moat, but is essentially the natural spillover of the main curve. Standardizing more OTC rates and FX risk into exchange clearing and tying customers in through margin and capital efficiency is indeed a structural tailwind. But it is still the existing network absorbing more existing demand, so it remains an extension of the first curve and does not constitute an independent new curve.

  A fair opposing point: does CME even need a second curve? For an infrastructure business that is already firmly positioned and generated about USD 4.19 billion of free cash flow in 2025, the absence of an explosive second curve is not fatal. The existing curve plus dividends and buybacks can still provide shareholders with reasonable returns. But Baillie Gifford is not looking for merely adequate. It asks where the next tenfold engine is, and by that standard CME has no convincing answer.

  Measured by Baillie Gifford's question of whether the second curve exists today, the answer is a fuzzy yes: candidates exist, but none qualifies. CME's future looks more like the same cash machine continuing to run steadily, with a few small motors added around the edges, rather than a new curve about to rise sharply from the ground. This is another key distinction between CME and a true high-growth stock.

  Jun 11, 2026
• QWhat is its core competitive advantage? Will this moat become wider or narrower over the next three to five years?6/10

  A

  Conclusion: CME's core competitive advantage is a three-part financial infrastructure moat built from liquidity concentration, centralized clearing, and regulatory licenses. It is very strong. Over the next three to five years, this moat should be broadly stable with slight widening, but marginal competition is rising in the single fattest profit pool, rates/Treasuries, so the right summary is that the main body widens while specific pressure points tighten.

  Start with what the moat is made of. The report breaks it into a multidimensional system, not a single advantage:

  • Network effects, strong: liquidity attracts liquidity. The deeper the order book and the more mature the clearing network, the harder it is to migrate away. In 2025, more than 93% of total volume came from the electronic platform CME Globex, and scale itself creates positive feedback.
  • Switching costs, medium-high: the cross-product margin and capital efficiency that come from connecting to CME Clearing are hard for clients to give up.
  • Licenses/regulatory barriers, extremely strong: exchange licenses, clearing licenses, systemically important financial market utility (SIFMU) status, and Federal Reserve cash account arrangements cannot be replicated quickly by spending money.
  • Cost structure, present: this is a high-fixed-cost, low-marginal-cost platform where incremental trading volume and data revenue convert into cash at high margins. Q1 2026 GAAP operating margin was about 69.7%, while ICE's exchange segment operating margin in the same period reached 79%, confirming that platform barriers across the sector are very thick.
  • Data and benchmarks, present and strengthening: Q1 2026 market data revenue reached a record USD 224 million, while CME Benchmark and CME Term SOFR further reinforce pricing power.

  Widening forces over the next three to five years: broader asset classes, faster-growing market data, benchmark rate tools, and the compounding effect of cross-product clearing efficiency. All of these make the ecosystem network denser.

  Narrowing risks, which must be faced honestly: the report names FMX as attacking CME's fattest rates profit pool through SOFR and U.S. Treasury futures; meanwhile, Q1 2026 rate per contract fell about 5% year over year, showing that the fee moat in any single product is not as invincible as it may appear.

  An important calibration after primary verification: the FMX threat is real, but it has not yet materially cut into CME. According to FOW, during a period of heightened volatility, FMX Treasury futures ADV at one point fell to about 928 contracts, more than halving from about 3,000 in March, as traders returned to the deeper liquidity of CME; CME's flagship SOFR contract ADV was about 9.80 million contracts. The gap is thousands of times. This confirms the strength of the network-effect moat in reverse: when liquidity matters most, capital runs to the deepest pool, not to the challenger. The most realistic path for a challenger is to break through in a local product segment, but taking some local share and shaking the core moat are two different things.

  Additional forward-looking risk signal over the next 4-8 quarters: in early June 2026, Kalshi won approval for bitcoin perpetual contracts, and TD Cowen warned that new products could erode the moats and valuation multiples of CME/ICE/CBOE. This is a marginal variable to keep watching, but it has not yet changed the core landscape.

  Measured by Baillie Gifford's question of whether the moat will widen or narrow over three to five years, CME's main body is widening through ecosystem, data, and clearing efficiency, while a specific area, rates fees, is under pressure and challengers have not yet taken a meaningful bite. This is a real, verifiable, and still slowly strengthening deep moat. It does not rely on whose software looks prettier; it relies on systemic barriers built from liquidity, clearing safety, and licenses.

  Jun 11, 2026
• QIf its core business were disrupted, does it have the gene for self-reinvention? How does it deal with mistakes and bad news?5/10

  A

  Conclusion: CME's attitude toward mistakes and bad news is candid and credible. But on the gene for self-reinvention, the honest answer is that CME is a mature infrastructure company that wins through a liquidity network and license-based moat. Its strength is defending steadily and correcting quickly, not tearing itself down and regenerating after the core is disrupted. This type of company is unlikely to face, and does not really need, that kind of life-or-death reinvention.

  Start with how it deals with mistakes and bad news. This can be verified directly, and CME performs well:

  The report notes that management proactively disclosed in the 10-K the temporary CME market halt in November 2025 caused by a cooling failure at a third-party data center operated by CyrusOne, rather than hiding this unflattering operating issue. A company that writes its own outage into the annual report and flags third-party facilities as a real risk is using a candid disclosure style. The report also notes that CME directly disclosed a roughly 5% year-over-year decline in rate per contract and FMX's challenge to the core rates profit pool. Putting bad news and competitive threats on the table, rather than polishing them away, is a sign of mature governance.

  Then consider the gene for self-reinvention. The implied premise in this chain question must be added, and the answer must be honest:

  The probability of the core business being disrupted is itself low, which reduces the need for reinvention. CME's moat is a multidimensional system of liquidity concentration, centralized clearing, SIFMU status, and regulatory licenses. In 2025, more than 93% of volume came from CME Globex. The report judges that it is not easily disrupted by pure technology. The most realistic threat is local liquidity migration and targeted challengers such as FMX, not the whole business being replaced overnight. In other words, CME faces the risk of being nibbled at, not overthrown.

  But if the question is whether CME could reinvent itself if the core were truly disrupted, the evidence is relatively weak. CME's growth history is one of gradual extension: broadening asset classes and thickening the data business on top of an existing clearing and liquidity network. It has not gone through a life-or-death episode where the core business collapsed and the company was forced to transform and regenerate. It has not demonstrated the gene to completely remake itself. The report also lists no Plan B after a core disruption. Compared with companies that genuinely have a reinvention gene, such as technology platforms that have repeatedly revolutionized themselves, CME is more a company that avoids disruption through structural barriers than one that is reborn through organizational resilience after disruption.

  It also stays rational when dealing with capital allocation mistakes. The report says management does not force itself to look for high-risk reinvestment projects, has been restrained in acquisitions in recent years, and does not expand for the sake of scale. This is a discipline of making fewer mistakes, and indirectly shows a clear understanding of the boundaries of its own capabilities.

  Measured by Baillie Gifford's lens of self-reinvention plus treatment of mistakes, CME scores well on candidly facing bad news and only average on the reinvention gene. That is precisely because its moat means it rarely needs to reinvent itself. This is a business that is hard to knock down, so it does not have to learn how to get back up, rather than a business that repeatedly falls and repeatedly comes back. For long-term holders, the former's certainty is an advantage. But under Baillie Gifford's strict test of whether a company can rise again after disruption, it is not outstanding.

  Jun 11, 2026
• QDoes management, especially the founder, have a long-term view and deep alignment with the company? Is it willing to sacrifice current profit for outcomes five to ten years from now?4/10

  A

  Conclusion: CME's management is operationally mature, disciplined in capital allocation, and fair to shareholders. Its interests are aligned with the company, but not deeply bound to it. This is not a founder-controlled company with heavy insider ownership, and there is little clear evidence that it is willing to sacrifice current profit for outcomes five to ten years out. It looks more like a conscientious professional management team than the kind of founder deeply tied to the company's fate and willing to make long-term bets that Baillie Gifford prefers.

  Start with interest alignment. This is a weakness that must be stated honestly:

  Based on the 2026 proxy statement, the report explicitly says this is not a company controlled by a heavily invested founder. No director, director nominee, or executive officer beneficially owns more than 1% of any class of shares. CEO Terrence A. Duffy beneficially owns about 55,594 Class A shares, plus a small number of Class B shares. At the current share price, the absolute value of this stake is negligible for a company with a market cap of about USD 95.6 billion (based on the closing share price of about USD 263.80 on June 10, 2026). So interest alignment exists, but it is not the strong alignment of Buffett-style large-shareholder governance. That is the report's wording and a fair judgment.

  That said, the institutional design of constraints is a plus:

  The report notes that the company has explicit ownership requirements for executives: the CEO must hold at least 5 times base salary, other named executives at least 3 times base salary, and executives and directors are prohibited from hedging company shares. Core financial metrics for executive compensation include Cash Earnings, relative TSR, and Net Income Margin. These mechanisms prevent management from easily betting against itself and link compensation to shareholder returns. They are institutional safeguards for alignment and partly offset the weakness of low ownership percentages.

  Then consider long-term orientation and willingness to sacrifice current profit for five- to ten-year outcomes. The evidence is neutral:

  The report describes management as operationally mature and conservative in capital allocation. Historically, it has favored large cash returns rather than aggressive acquisitions, has been restrained in recent M&A, and does not expand for the sake of scale. This shows strong discipline and no careless cash burn. But it also means the company has not shown an aggressive posture of sacrificing current profit and investing heavily for a large opportunity 10 years out. CME is an asset-light business by nature; the report discloses 2025 capex of only about USD 84 million. It is simply not a business where large forward-looking investment is needed, so the question of sacrificing short-term profit for the long term has little room to show up. Its long-termism is expressed more through steady stewardship and ongoing cash returns than through bold bets on the future.

  One honest blemish in capital allocation discipline:

  The report notes that management repurchased 1.8385 million shares in Q1 2026 at an average price of about USD 291.6, spending about USD 538.7 million. This price was already near the upper end of the report's intrinsic value range and was not cheap. It looked more like capital return at a high-quality company than aggressive bargain hunting when the stock was undervalued. The repurchase-price discipline was ordinary, and is another observation point beyond interest alignment.

  Measured by Baillie Gifford's lens of founder long-term alignment and willingness to sacrifice today for the future, CME fails on deep alignment and is unremarkable on sacrificing short-term profit for long-term outcomes, while passing on honesty, rationality, and not wasting money. It is a trustworthy steward, not a captain in the same boat who has staked personal wealth on the next 10 years. That is enough for holders seeking certainty, but under Baillie Gifford's preference for founder spirit, it is a clear deduction.

  Jun 11, 2026
• QIf it disappeared tomorrow, how much would customers miss it? Is its growth model sustainable and not dependent on harming society or fighting regulators?6/10

  A

  Conclusion: If CME disappeared tomorrow, institutional customers would miss it badly. It is almost indispensable in rates, equity-index, and commodity risk management. At the same time, its growth model does not depend on harming society and is highly dependent on, rather than opposed to, regulation, giving it strong social and regulatory sustainability. This is one of the rare questions in the Baillie Gifford set where CME scores well on both dimensions.

  This chain question needs to be split into two premises, indispensability and social/regulatory sustainability, and answered separately:

  First: indispensability is very high. How much customers would miss it depends on whether there is an equivalent substitute. The report's evidence is that CME operates four derivatives exchanges, CME, CBOT, NYMEX, and COMEX, plus a central counterparty clearing house, providing a full infrastructure stack from trading, clearing, risk management, and settlement to market data. In 2025, more than 93% of volume came from CME Globex, and liquidity, clearing networks, and cross-product margin efficiency form a deep moat. In institutional markets, a CME contract itself is the standard for liquidity and risk management.

  The hardest evidence comes from the reverse side of the FMX challenge: according to FOW, when market volatility intensified, traders moved orders back from challenger FMX to the deeper liquidity of CME. FMX Treasury futures ADV at one point fell to about 928 contracts, while CME's flagship SOFR contract ADV was about 9.80 million contracts. In other words, the more critical the moment and the greater the risk, the more customers depend on CME's depth of liquidity. That is direct evidence that CME would be intensely missed if it disappeared tomorrow. Rates, commodity, and equity-index exposures would have nowhere comparable to hedge, creating acute pain for the entire financial system.

  Second: social/regulatory sustainability is strong and directionally positive. Here the question is whether growth depends on harming society or regulators:

  • It does not harm society; it provides a public good. CME's business is essentially helping banks, asset managers, and industrial hedgers manage price, rate, and exchange-rate risk, while reducing systemic counterparty risk through central clearing. It provides infrastructure for the real economy and financial stability, rather than growing by exploiting users or creating externalities. Its revenue comes from real risk-transfer demand, giving it a positive social role.

  • It moves in the same direction as regulators, rather than fighting them. The report notes that CME has systemically important financial market utility (SIFMU) status and Federal Reserve cash account arrangements. Regulatory licenses themselves are part of its extremely strong moat. Its growth is built on being trusted by regulators and carrying a systemically important function. That is completely different from businesses that rely on regulatory arbitrage or pushing red lines to expand. Regulation is its moat, not its enemy.

  An honest boundary on the risks: sustainability does not mean zero risk. The report clearly lists regulation and tax policy as key uncertainties. Any transaction tax, change in 60/40 tax treatment, or new clearing or market-structure rule could affect customer trading costs and volume. In early June 2026, Kalshi won approval for bitcoin perpetual contracts, and TD Cowen warned that newly approved products could erode traditional exchanges. These are risks from regulatory-environment changes, but by nature they remain competition and policy volatility within the compliance framework. They do not change the basic judgment that CME's growth does not rely on harming society.

  Measured by Baillie Gifford's dual lens of how much customers would miss it tomorrow and whether growth is sustainable without harming society or regulators, CME scores highly on both. It is an irreplaceable hub for institutional risk management, and its growth model is clean and symbiotic with regulation. This is one of the strongest fundamental pillars of CME as high-quality infrastructure, and it is why the company remains worth watching over the long term even when the price is not cheap.

  Jun 11, 2026
• QWhat are the unit economics of this business, including gross margin and incremental returns? Do they improve or worsen with scale? Where does the money it earns go?8/10

  A

  Conclusion: CME's unit economics are among the best in U.S. equities. It has high fixed costs and near-zero marginal costs, margins keep rising as the business scales, meaning growth makes it more profitable, and incremental returns are extremely high. Almost all cash generated is returned to shareholders through dividends, variable dividends, and buybacks, rather than being trapped in heavy assets. This is CME's least debatable strength.

  Start with the essence of the unit economics: this is a high-fixed-cost, low-marginal-cost platform. The report notes that management explicitly disclosed that the cost structure is largely fixed in the short term. Major 2025 expenses were about USD 907 million for compensation, about USD 283 million for technology, and about USD 371 million for licensing and fee agreements. That means every additional contract matched and every additional data product sold carries very low incremental cost, so most incremental revenue flows directly into profit. This is the engine that drives margins higher as scale increases.

  Evidence that margins rise with scale, verified from primary sources:

  • CME officially disclosed 2025 full-year revenue of about USD 6.5 billion, operating income of about USD 4.2 billion, net income of about USD 4.1 billion, and diluted EPS of USD 11.16, corresponding to an operating margin of about 65%.
  • Q1 2026 revenue was USD 1.88 billion (+14%), net income was USD 1.154 billion (+21%), and diluted EPS was USD 3.18. Net income growth of 21% was meaningfully faster than revenue growth of 14%, a live example of scale increasing and margins rising; the report estimates GAAP operating margin for the quarter at about 69.7%.

  Incremental returns are extremely high and do not depend on heavy capital:

  The report discloses 2025 operating cash flow of about USD 4.277 billion, capex of only about USD 84 million, free cash flow of about USD 4.194 billion, and FCF/net income of about 1.03 times; net property and equipment in 2025 was only about USD 363 million. There is almost no inventory, and the company does not need to keep spending heavily on capacity to grow. This is a textbook case of growing more profitable, not growing more capital-hungry. The report estimates approximate ROE rose to about 14.7%, with adjusted ROIC roughly in the low double digits.

  Do economics improve or worsen with scale? They clearly improve:

  The report records GAAP operating margin rising from 61.6% in 2023 to 64.9% in 2025, then to about 69.7% in Q1 2026. Scale is not bringing diminishing marginal returns; it is bringing continued margin expansion and stronger cash conversion. This is the most attractive property of a platform business.

  Where does the money it earns go? Almost all of it is returned to shareholders:

  The report characterizes CME's capital allocation clearly: not major acquisitions, but large cash returns. Specifically, in Q1 2026 the company paid about USD 2.7 billion in dividends and repurchased about USD 536 million of stock. The report also notes that in February 2026, CME announced a quarterly dividend of USD 1.30 per share plus an annual variable dividend of USD 6.15 per share. Capital is not being trapped in low-return projects; it is being returned to shareholders in cash, confirming the asset-light, high-distribution nature of the business. The only criticism is ordinary buyback-price discipline, as the report says the Q1 2026 average repurchase price of about USD 291.6 was already not cheap. But that is a question of whether the money was spent at an attractive price, not a challenge to the core judgment that unit economics are exceptional.

  Measured by Baillie Gifford's lens of unit economics, incremental returns, scale effects, and where the money goes, CME is close to full marks. A high-fixed-cost platform, near-zero marginal costs, margins rising with scale, cash conversion above 100%, and full cash return to shareholders make this a structurally outstanding business. Its problem has never been whether it makes money. The question is how high a multiple the market is willing to pay for this cash machine, which is a valuation question, not a unit-economics question.

  Jun 11, 2026
• QWhat conditions would have to hold simultaneously for it to rise fivefold over 10 years? Are those conditions realistic? What expectations are embedded in today's share price?3/10

  A

  Conclusion: For CME to rise fivefold over 10 years, about 17.5% annualized, it would need earnings to compound at about 13-15% annually while the valuation multiple does not contract and perhaps even expands. Both conditions conflict with CME's structural reality, so a fivefold return over 10 years is highly unrealistic. Today's share price embeds only the reasonable expectation of mid- to high-single-digit growth plus preservation of a high-quality platform multiple, far from a fivefold narrative.

  First quantify the conditions needed for a fivefold increase over 10 years. Starting from the June 10, 2026 closing price of about USD 263.80 and market cap of about USD 95.6 billion, a fivefold increase over 10 years means a share price of about USD 1,319 and annualized total return of about 17.5% on price return. Even including a dividend yield of about 4%, the price component would still need about 13-14% annualized. The simultaneous conditions are:

  Condition 1: earnings must compound at about 13-15% annually for 10 straight years. But the report discloses that CME's 2020-2025 5-year revenue CAGR was only about 5.9%, while net income grew about 14%, with part of that high net-income growth helped by recent tailwinds from active rates, geopolitical, and commodity volatility. 2025 full-year revenue was about USD 6.5 billion and EPS was USD 11.16. To run revenue/earnings steadily at 13-15% for 10 years would require a structural leap. The report instead judges growth as natural expansion with global risk exposures plus cyclical amplification from volume, structurally in the mid- to high-single digits. This condition is almost impossible to satisfy.

  Condition 2: the valuation multiple must not contract and may need to expand. CME currently trades at about 22.5 times P/E, which the report judges as reasonable-to-somewhat-expensive for an excellent company. A fivefold increase over 10 years must come from either racing earnings or a further multiple lift. But the report clearly says the most fragile assumption is whether the market can continue to maintain a high-quality platform multiple of 24-26 times. If growth falls back and the exit multiple compresses to 20-22 times, long-term total return may be only mid-single-digit annualized. The multiple is more likely to be a headwind than a tailwind.

  Condition 3: the fee and competitive environment must not worsen. The report discloses that Q1 2026 rate per contract fell about 5% year over year, while FMX is entering the core rates profit pool. A fivefold outcome would also require all these headwinds to reverse, which is likewise unrealistic.

  The combined probability of these three conditions is extremely low. The report's own 10-year annualized total return framework is: conservative 4%-6%, base case 7%-9%, optimistic 10%-12%. Even the optimistic scenario of 10%-12% is far below the roughly 17.5% needed for a fivefold return. In other words, CME needs an optimistic scenario just to reach a 10-year doubling; a 10-year fivefold return is simply outside its capability range.

  So what expectations are embedded in today's share price? Not a fivefold story, but a fairly moderate expectation: the market prices CME at about 22.5 times P/E, implying continuation of a deep moat, mid- to high-single-digit growth, high cash distributions, and no major contraction in the high-quality platform multiple. The report estimates an earnings yield of about 4% based on the current P/E, below the then-current 10-year U.S. Treasury yield of about 4.56%. It is worth noting that the share price has fallen about 9% from the report snapshot of USD 291.23 on May 22, 2026 to USD 263.80, partly because Kalshi's approval for bitcoin perpetual contracts in early June 2026 raised concerns about exchange valuation multiples. Even after the pullback, relative to the report's intrinsic value range of USD 245-275 as fair value and USD 210-240 as an ideal buying range, the current price remains in the upper part of fair value rather than in a deeply undervalued zone with fivefold upside imagination.

  Measured by Baillie Gifford's lens of what conditions must hold for a 10-year fivefold return and what today's price embeds, CME clearly fails. A fivefold return would require racing earnings plus multiple expansion, while CME is structurally a steady compounder with a fairly full multiple. Today's price embeds expectations for reasonable quality and reasonable return; it does not contain, and should not contain, any fivefold narrative. This is a high-quality cash machine, but it cannot provide the upward slope Baillie Gifford wants.

  Jun 11, 2026
• QWhy has the market not realized all this yet? Is it failing to understand, looking down on it, or not looking far enough? What could become the narrative inflection point?3/10

  A

  Conclusion: In CME's case, the market actually understands the story quite well. Its moat, cash generation, and quality are already fully priced in, so the honest answer is that there is no overlooked perception gap. If anything, the current price is closer to fair, and at times somewhat elevated, valuation. The true narrative inflection point is not when the market discovers how good CME is, but when expectations for growth, competition, or regulation are recalibrated. That recalibration can move downward as well as upward.

  Baillie Gifford's question assumes the market has not yet recognized the greatness of the company. Applied to CME, that premise itself needs to be rejected honestly:

  The market is not failing to understand, looking down on it, or failing to look far enough. It sees it clearly. The evidence is that valuation already reflects quality: the report shows CME's current P/E at about 22.5-24.85 times, in the mid-to-upper valuation band among major U.S. exchange operators, above ICE at about 22.27 times and below NDAQ at about 27.41 times and CBOE at about 30.52 times. NDAQ's P/E was about 25.84 times in early June 2026, and ICE Q1 2026 net revenue rose 20%, with exchange segment operating margin reaching 79%. The market fully recognizes the quality of the entire sector and assigns it a premium. CME is not a dusty hidden gem. It is a polished, visibly high-quality asset with a substantial price tag. The report's conclusion is exactly that it is a good company at an ordinary-to-expensive price, not a significantly undervalued one.

  If there is no positive perception gap, where does the perception gap exist? It is actually at both ends of the disagreement:

  • The bearish-side perception gap is more realistic: the market may be underestimating the drag from cyclicality and competition. The report's strongest bear case is that CME's rich recent profits benefited greatly from an unusually active environment across global rates, geopolitics, and commodities. If volatility recedes, rate per contract keeps falling, already down about 5% year over year in Q1 2026, and FMX or others take away some high-value liquidity, the result may be a company that remains excellent while shareholder returns are mediocre. This direction of not looking far enough is real and points to downside.

  • The bullish-side perception gap is weaker: some may argue that the market underestimates the resilience of the market data business and the compounding value of benchmark pricing power. Q1 2026 market data revenue reached a record USD 224 million. But this segment is only about 12% of revenue and cannot support a re-rating narrative, so the evidence in this direction is weaker.

  What could become the narrative inflection point? The implied premise in this chain question must be filled in by separating upside and downside paths:

  • Downside inflection, which deserves more vigilance: several consecutive quarters of share loss in core rates/Treasury contracts, a persistent decline in fees that data revenue cannot offset, a major operating or cyber incident, loss of exclusivity in key index licensing, or a long-term weakening of the volatility environment. Any one of these could lead the market to reprice CME from a perpetual high-quality platform into a mature cyclical infrastructure business, compressing the multiple from 24-26 times toward 18-22 times. In early June 2026, Kalshi won approval for bitcoin perpetual contracts and TD Cowen warned that new products could erode valuation multiples for CME/ICE/CBOE. The share price then fell from the report snapshot of about USD 291 to about USD 263.80 on June 10, 2026, which is a real-time sample of a downside narrative inflection being triggered.

  • Upside inflection, with stricter conditions: if the price overshoots downward on those concerns into the report's ideal buying range of USD 210-240, while fundamentals prove that competition and fee concerns were exaggerated, it could create a positive inflection from a high-quality asset being wrongly sold off and then recovering. But that would be a price inflection, not a perception inflection where the market finally discovers its greatness.

  Measured by Baillie Gifford's question of why the market has not realized this and what the narrative inflection point is, the honest answer for CME is that there is no overlooked greatness. The market has long understood it and has priced it fully, at times somewhat richly. It is not a growth stock waiting to be discovered; it is a transparently priced high-quality blue chip that wins through cash distributions and steady compounding. The narrative inflection is more likely to come from a downward recalibration of growth/competition expectations, which has already partly happened, than from the market suddenly recognizing its quality. For long-term holders, the opportunity lies in when the price falls below a margin of safety, not in when a perception gap closes, because the perception gap is already small.

  Jun 11, 2026